Abstract
Twenty-seven new ortho-hydroxy chalcone and a series of indole-chalcone derivatives have been designed and synthesized. The structures of all newly-synthesized compounds were characterized by different spectroscopic techniques and the interactions with tubulin were evaluated for antiproliferative activities in vitro. The structure–activity relationships were elucidated for compounds with various substituents on the benzene ring of the aldehyde moiety at positions C-3, C-4 and C-5 with constant o-OH. The best inhibition results of ring bioisoterism for cancer cell growth were obtained for compounds 4c, 5j, and 6a with substituents m-tBu, Br and p-OCH3, respectively. Their antiproliferative activity was evaluated in MCF-7 cells, with compound 5j showing cytotoxicity activity comparable to that of reference compound paclitaxel. A computational study was carried out, for calculation of pharmacophore pattern, prediction of pharmacokinetic properties and toxicity. The results of the target compounds are followed by docking studies that have provided structural recommendations for designing new antiproliferative chalcones.
Highlights
-
A new series of ortho-hydroxy chalcones (4a–6j) and a series of indole chalcones (9a–d) were designed and synthesized.
-
5-Nitrochalcone (7a–c) were readily reduced to amine to increase solubility in biological media.
-
A bioisosteric replacement was found to have enhanced in vitro inhibition potential.
-
The binding mode of Colchicine and the ortho-hydroxy chalcone derivatives to tubulin has been compared.
Similar content being viewed by others
References
Amos LA. Microtubule structure and its stabilisation. Org Biomolecular Chem. 2004;2:2153–60.
Stanton RA, Gernert KM, Nettles JH, Aneja R. Drugs that target dynamic microtubules: a new molecular perspective. Medicinal Res Rev. 2011;31:443–81.
Voitovich YV, Shegravina ES, Sitnikov NS, Faerman VI, Fokin VV, Schmalz HG, Combes S, Allegro D, Barbier P, Beletskaya IP, Svirshchevskaya EV. Synthesis and biological evaluation of furanoallocolchicinoids. J Med Chem. 2015;58:692–704.
Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer. 2010;10:194–204.
Seligmann J, Twelves C. Tubulin: an example of targeted chemotherapy. Futur Med Chem. 2013;5:339–52.
McIntosh JR, Grishchuk EL, West RR. Chromosome-microtubule interactions during mitosis. Annu Rev Cell Dev Biol. 2002;18:193–219.
Romagnoli R, Baraldi PG, Salvador MK, Preti D, Aghazadeh Tabrizi M, Brancale A, Fu XH, Li J, Zhang SZ, Hamel E, Bortolozzi R. Discovery and optimization of a series of 2-aryl-4-amino-5-(3′, 4′, 5′-trimethoxybenzoyl) thiazoles as novel anticancer agents. J Med Chem 2012;55:5433–45.
Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov. 2010;9:790–803.
Yue QX, Liu X, Guo DA. Microtubule-binding natural products for cancer therapy. Planta Med. 2010;76:1037–43.
Kaur R, Kaur G, Gill RK, Soni R, Bariwal J. Recent developments in tubulin polymerization inhibitors: an overview. Eur J Med Chem. 2014;87:89–124.
Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253–65.
Löwe J, Li H, Downing KH, Nogales E. Refined structure of αβ-tubulin at 3.5 Å resolution. J Mol Biol. 2001;313:1045–57.
Gigant B, Wang C, Ravelli RB, Roussi F, Steinmetz MO, Curmi PA, Sobel A, Knossow M. Structural basis for the regulation of tubulin by vinblastine. Nature. 2005;435:519–22.
Kavallaris M, Verrills NM, Hill BT. Anticancer therapy with novel tubulin-interacting drugs. Drug Resistance Updates. 2001;4:392–401.
Wang G, Li C, He L, Lei K, Wang F, Pu Y, Yang Z, Cao D, Ma L, Chen J, Sang Y. Design, synthesis and biological evaluation of a series of pyrano chalcone derivatives containing indole moiety as novel anti-tubulin agents. Bioorg Med Chem. 2014;22:2060–79.
Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. Br J Pharmacol. 2011;162:1239–49.
Patani GA, LaVoie EJ. Bioisosterism: a rational approach in drug design. Chem Rev. 1996;96:3147–76.
Meanwell NA. Synopsis of some recent tactical application of bioisosteres in drug design. J Med Chem. 2011;54:2529–91.
Gomes MN, Muratov EN, Pereira M, Peixoto JC, Rosseto LP, Cravo PV, Andrade CH, Neves BJ. Chalcone derivatives: promising starting points for drug design. Molecules. 2017;22:1210.
Zhou B, Xing C. Diverse molecular targets for chalcones with varied bioactivities. Med Chem. 2015;5:388.
Yan J, Chen J, Zhang S, Hu J, Huang L, Li X. Synthesis, evaluation, and mechanism study of novel indole-chalcone derivatives exerting effective antitumor activity through microtubule destabilization in vitro and in vivo. J Med Chem. 2016;59:5264–83.
Burmaoglu S, Algul O, Anıl DA, Gobek A, Duran GG, Ersan RH, Duran N. Synthesis and anti-proliferative activity of fluoro-substituted chalcones. Bioorg Med Chem Lett. 2016;26:3172–6.
Hofmann E, Webster J, Do T, Kline R, Snider L, Hauser Q, Higginbottom G, Campbell A, Ma L, Paula S. Hydroxylated chalcones with dual properties: xanthine oxidase inhibitors and radical scavengers. Bioorg Med Chem. 2016;24:578–87.
Srinivasan B, Johnson TE, Lad R, Xing C. Structure− activity relationship studies of chalcone leading to 3-hydroxy-4, 3′, 4′, 5′-tetramethoxychalcone and its analogues as potent nuclear factor κB inhibitors and their anticancer activities. J Med Chem 2009;52:7228–35.
Bhagat S, Sharma R, Sawant DM, Sharma L, Chakraborti AK. LiOH· H2O as a novel dual activation catalyst for highly efficient and easy synthesis of 1, 3-diaryl-2-propenones by Claisen–Schmidt condensation under mild conditions. J Mol Catal A Chem. 2006;244:20–4.
Ono M, Haratake M, Mori H, Nakayama M. Novel chalcones as probes for in vivo imaging of β-amyloid plaques in Alzheimer’s brains. Bioorg Med Chem. 2007;15:6802–9.
Kumar D, Kumar NM, Akamatsu K, Kusaka E, Harada H, Ito T. Synthesis and biological evaluation of indolyl chalcones as antitumor agents. Bioorg Med Chem Lett. 2010;20:3916–9.
Da Violante G, Zerrouk N, Richard I, Provot G, Chaumeil JC, Arnaud P. Evaluation of the cytotoxicity effect of dimethyl sulfoxide (DMSO) on Caco2/TC7 colon tumor cell cultures. Biol Pharm Bull. 2002;25:1600–3.
Wang H, Wang Y, Chen ZY, Chan FL, Leung LK. Hydroxychalcones exhibit differential effects on XRE transactivation. Toxicology. 2005;207:303–13.
Karthikeyan C, Narayana Moorthy SH, Ramasamy N, Vanam S, Manivannan U, Karunagaran E, Trivedi D. P. Advances in chalcones with anticancer activities. Recent Pat anti-cancer drug Discov. 2015;10:97–115.
Shin SY, Kim JH, Yoon H, Choi YK, Koh D, Lim Y, Lee YH. Novel antimitotic activity of 2-hydroxy-4-methoxy-2′, 3′-benzochalcone (HymnPro) through the inhibition of tubulin polymerization. J Agric Food Chem. 2013;61:12588–97.
Gomes MN, Muratov EN, Pereira M, Peixoto JC, Rosseto LP, Cravo PV, Andrade CH, Neves BJ. Chalcone derivatives: promising starting points for drug design. Molecules. 2017;22:1210.
Nielsen SF, Boesen T, Larsen M, Schønning K, Kromann H. Antibacterial chalcones–bioisosteric replacement of the 4′-hydroxy group. Bioorg Med Chem. 2004;12:3047–54.
Nguyen TL, McGrath C, Hermone AR, Burnett JC, Zaharevitz DW, Day BW, Wipf P, Hamel E, Gussio R. A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach. J Med Chem. 2005;48:6107–16.
Rosen MD, Venkatesan H, Peltier HM, Bembenek SD, Kanelakis KC, Zhao LX, Leonard BE, Hocutt FM, Wu X, Palomino HL, Brondstetter TI. Benzimidazole-2-pyrazole HIF prolyl 4-hydroxylase inhibitors as oral erythropoietin secretagogues. ACS Med Chem Lett. 2010;1:526–9.
Farce A, Loge C, Gallet S, Lebegue N, Carato P, Chavatte P, Berthelot P, Lesieur D. Docking study of ligands into the colchicine binding site of tubulin. J Enzym Inhibit Med Chem. 2004;19:541–7.
Majcher U, Klejborowska G, Moshari M, Maj E, Wietrzyk J, Bartl F, Tuszynski JA, Huczyński A. Antiproliferative activity and molecular docking of novel double-modified colchicine derivatives. Cells 2018;7:192.
McLoughlin EC, O’Boyle NM. Colchicine-binding site inhibitors from chemistry to clinic: a review. Pharmaceuticals. 2020;13:8.
Yaeghoobi M, Frimayanti N, Chee CF, Ikram KK, Najjar BO, Zain SM, Abdullah Z, Wahab HA, Rahman NA. QSAR, in silico docking and in vitro evaluation of chalcone derivatives as potential inhibitors for H1N1 virus neuraminidase. Med Chem Res. 2016;25:2133–42.
Morgan DM. Tetrazolium (MTT) assay for cellular viability and activity. In Polyamine protocols. Humana Press; 1998. pp. 179–184.
Wang T, Li Z, Cvijic ME, Krause C, Zhang L, Sum CS. Measurement of β-arrestin recruitment for GPCR targets. Assay Guidance Manual, Bethesda (MD). Eli Lilly & Company and the National Center for Advancing Translational Sciences, 2004.
Muškinja JM, Burmudžija AZ, Baskić DD, Popović SL, Todorović DV, Zarić MM, Ratković ZR. Synthesis and anticancer activity of chalcone analogues with sulfonyl groups. Med Chem Res. 2019;28:279–91.
Sheldrick GM. Crystal structure refinement with SHELXL. Acta Cryst. 2015;71:3–8.
Spek AL. Structure validation in chemical crystallography. Acta Cryst. 2009;65:148–55.
Acknowledgements
Funding
The authors would like to thank the Malaysian Government for the Fundamental Research Grant Scheme (FRGS) with project code FRGS/1/2019/STG01/USM/02/16 which was used to finance this research work.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Jumaah, M., Khairuddean, M., Owaid, S.J. et al. Design, synthesis, characterization and cytotoxic activity of new ortho-hydroxy and indole-chalcone derivatives against breast cancer cells (MCF-7). Med Chem Res 31, 517–532 (2022). https://doi.org/10.1007/s00044-021-02834-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00044-021-02834-2